Skip to contentpdufa.bio

Pelareorep

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Pelareorep is an Oncolytics Biotech Inc program in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). Its next catalyst is a Readout in Q4 2026.

ONCY catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: Newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC); Second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer; Second-line and later squamous cell anal carcinoma (SCAC). Sponsor: Oncolytics Biotech Inc (ONCY). We track 3 catalyst events for this program: 3 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026ONCYReadout · Q4 2026ONCYReadout · Q2 2027ONCY

Questions

When is Pelareorep's next FDA decision or readout?

The next tracked catalyst for Pelareorep is a Readout in Q4 2026.

What happened at Pelareorep's most recent FDA decision?

No FDA decision for Pelareorep is in our archive yet.

What is Pelareorep used for?

In our records Pelareorep is under review or in development for Newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC); Second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer.

Who makes Pelareorep?

Oncolytics Biotech Inc (ONCY).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.